UCB's Global Corporate Website
Welcome to UCB in the United States

May

17

Prioritizing Mental Health for our People, Patients, and Purpose

Mental health is top of mind at UCB as we work to prioritize the well-being of our people and the patients we serve. A core pillar of our sustainable business approach, we understand that delivering innovative solutions for patients begins with supporting the physical, mental, and social well-being of our employees, their families, and communities, now and in the future. This Mental Health Awareness Month, learn how we’re supporting mental wellness for our people, patients, and our purpose. 

May

12

Recognizing the Less Common, but Equally Burdensome, Forms of Arthritis During Arthritis Awareness Month

May

10

Recognizing our Rising Star and Luminary: Kerry Black and Brooke Fleming Recognized by the Healthcare Businesswomen’s Association

UCB congratulates Kerry Black, Head of Early Solutions U.S. Operations, and Brooke Fleming, Head of Omnichannel Marketing and Digital Enablement, for their recognition by the Healthcare Businesswomen's Association (HBA) as 2022 Luminary and Rising Star, respectively. 

May

10

UCB presents efficacy and safety results for zilucoplan and rozanolixizumab in generalized myasthenia gravis

May

02

JAMA Neurology Publishes Phase 3 Study Results on the Efficacy and Safety of FINTEPLA® (fenfluramine) Oral Solution in Lennox-Gastaut Syndrome (LGS)

Apr

22

Contributing to Environmental Sustainability this Earth Day and Every Day

Apr

13

UCB Community Health Fund Supports U.S. Organizations Addressing Mental Health and Young People

UCB recently announced the funding recipients for the UCB Community Health Fund’s 2021 call for projects, focused on the needs of vulnerable young people in the wake of COVID-19. Three U.S.-based organizations will receive support from the Fund for projects addressing the mental health of vulnerable young people. 

 

Apr

02

Advancing Our Mission to Cure Epilepsy

With nearly 30 years of experience in epilepsy, UCB can and will unlock what's possible for the millions of people living with epilepsy, so their reality can be free from seizures and the other debilitating and unpredictable impacts of the disease. Hear from Mike Davis, Head of U.S. Neurology and Rare, share our plan to impact the underlying causes of the disease and to discover, develop, and deliver highly differentiated medicines that will transform and, ultimately, cure the disease, so that people living with epilepsy can live their ideal life, every day.

Apr

01

UCB Showcases Strength of Broad Neurology Portfolio at 74th American Academy of Neurology (AAN) Annual Meeting

Mar

28

FINTEPLA® (fenfluramine) Oral Solution Now FDA Approved for Treatment of Seizures Associated with Lennox-Gastaut Syndrome (LGS)